Comparative Pharmacology
Head-to-head clinical analysis: OZEMPIC versus VICTOZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OZEMPIC versus VICTOZA.
OZEMPIC vs VICTOZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the action of endogenous GLP-1, which increases insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety. The primary mechanism is activation of GLP-1 receptors on pancreatic beta cells, leading to glucose-dependent insulin release.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
1 mg subcutaneously once weekly, starting at 0.25 mg once weekly for 4 weeks, then 0.5 mg once weekly for at least 4 weeks before escalating to 1 mg.
Subcutaneous injection: 0.6 mg once daily for 1 week, then increase to 1.2 mg once daily. May further increase to 1.8 mg once daily if needed for glycemic control.
None Documented
None Documented
Terminal elimination half-life approximately 1 week (5–7 days) in subcutaneous dosing, allowing once-weekly administration. Steady state reached after 4–5 weeks.
After subcutaneous administration, the terminal elimination half-life is approximately 13 hours, supporting once-daily dosing.
Primarily renal (80%) and biliary/fecal (20%). Unchanged parent drug accounts for ~5-10%; majority is degraded into small peptides/amino acids.
Liraglutide is eliminated via degradation by general proteolysis and not by specific enzymes; the intact drug is not excreted in urine or feces. Degraded metabolites are excreted via urine and feces.
Category C
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist